Home > People > CAS YIPA Members


  Jiyun Shi, Ph.D, Associate Prof. 

  Member of the Youth Innovation Promotion Association of CAS
  Institute of Biophysics, Chinese Academy of Sciences
  IBP-PKU Joint Lab of Molecular Imaging and Translational Medicine
  E-mail: shijiyun(AT)ibp.ac.cn
  Tel: (+86)(10)64888340;
  15 Datun Road, Chaoyang District, Beijing, 100101, China


Biography & Introduction


Molecular Imaging, Tumor Targeted Radiotherapy, Translational Nuclear Medicine.


2008/9-2011/7 Ph.D. in Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China   

2004/9-2007/7 Joint training Master student in Radiopharmaceuticals, China Institute of Atomic Energy and Peking University, China   

2000/9-2004/7 Undergraduate Student in Chemistry, Chemistry College, Jilin University, Jilin Province, China



Associate Professor, Interdisciplinary Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China


Assistant Professor, Medical and Health Analytical Center & Medical Isotopes Research Center, Peking University, Beijing 100191, China


Research Fellow, Molecular Imaging and Nanomedicine Laboratory, University of Toronto & University Health Network, Toronto, Canada

Mentor: Prof. Gang Zheng


Visiting Scholar, Radiochemistry Laboratory, School of Health Sciences, Purdue University, Indiana, USA

Mentor: Prof. Shuang Liu


  2011 Outstanding Graduate Award, Peking University

  2011 The Promising Academic Research Talent Award, Peking University(HSC)

  2011 Top Prize University Scholarship (top 5%)

  2010 Scholarship Award for Excellent Doctoral Student granted by Ministry of  Education (¥30,000/year)

  2010 Academic Innovation Award, Peking University

  2010 Merit Student Award, Peking University

  2009 International Travel Award of 18th International Symposium on Radiopharmaceutical Sciences, International Atomic Energy Agency (IAEA)

  2009 Academic Innovation Award, Peking University

  2016 Gold Medal of the National Science and Technology Workers Innovation and Entrepreneurship Competition of the 18th China Association for Science and Technology Annual Conference


Source: National Natural Science Foundation (General Program) 

Title: A Novel Molecular Probe for Imaging Diagnosis and Therapeutic Evaluation of HER2-Positive Tumors

Role: Principal Investigator

Period Covered: 01/2020 to 12/2023

Source: National Natural Science Foundation (General Program)
Source: Beijing Natural Science Foundation (General Program)

Title: A Novel Molecular Probe for PET Imaging of Highly Metastatic Tumor Novel

Role: Principal Investigator

Period Covered: 01/2016 to 12/2019

Source: Beijing Natural Science Foundation (General Program)

Title: A Novel Molecular Probe Targeting Tumor Integrin αvβ3 Expression

Role: Principal Investigator

Period Covered: 01/2014 to 12/2016

Source: National Natural Science Foundation Youth Fund

Title: Porphyrin-Based Multifunctional Molecular Probe Targeting Tumor Integrin αvβ3 Expression

Role: Principal Investigator

Period Covered: 01/2012 to 12/2015

China Food and Drug Administration, a class 1 new drug clinical trial approval (drug name: 99mTc-3PRGD2 injection), approval number: 2018L02484. Currently in clinical phase III trials.  


14 patents: ZL200810239036.X; ZL200910077039.2; ZL2014100840659; ZL201310304250.X; ZL201410084837.9; ZL201611095315.4; ZL2017103346344; ZL2017103341374; ZL201710713055.0; ZL201611095338.5; ZL201711113966.6; 201910378947.9; 2019107773304; 2019110099872.

SELECTED SCIENTIFIC PUBLICATIONS (# Co-first Author,* Corresponding Author)

1. Gao, H.; Luo, C.; Yang, G.; Du, S.; Li, X.; Zhao, H.; Shi, J.*; Wang, F*. Improved in Vivo Targeting Capability and Pharmacokinetics of (99m)Tc-Labeled isoDGR by Dimerization and Albumin-Binding for Glioma Imaging. Bioconjugate chemistry 2019, 30, 2038-2048.

2. Zhao H, Gao H, Zhai L, Liu X, Jia B, Shi J*, Wang F*. (99m)Tc-HisoDGR as a Potential SPECT Probe for Orthotopic Glioma Detection via Targeting of Integrin α5β1. Bioconjug Chem. 2016 May 18;27(5):1259-66.

3. Shi J, Wang F, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep. 2016;2(1):1-20. Review.

4. Jing L#, Shi J#, Fan D, Li Y, Liu R, Dai Z*, Wang F*, Tian J*. (177)Lu-Labeled Cerasomes Encapsulating Indocyanine Green for Cancer Theranostics. ACS Appl Mater Interfaces. 2015 Oct 7;7(39):22095-105.

5. Fan D, Zhang X, Zhong L, Liu X, Sun Y, Zhao H, Jia B, Liu Z, Zhu Z, Shi J*, Wang F*. (68)Ga-Labeled 3PRGD2 for Dual PET and Cerenkov Luminescence Imaging of Orthotopic Human Glioblastoma. Bioconjug Chem. 2015 Jun 17;26(6):1054-60.

6. Shi J, Fan D, Dong C, Liu H, Jia B, Zhao H, Jin X, Liu Z, Li F, Wang F. Anti-tumor effect of integrin targeted 177Lu-3PRGD2 and combined therapy with endostar. Theranostics. 2014, 4(3):256-66.

7. Shi J#, Jin Z#, Liu X, Fan D, Sun Y, Zhao H, Zhu Z, Liu Z, Jia B, Wang F. PET Imaging of Neovascularization with (68)Ga-3PRGD2 for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy. Mol Pharm. 2014 Nov 3;11(11):3915-22.

8. Wu M#, Shi J#, Fan D, Zhou Q, Wang F, Niu Z, Huang Y. Biobehavior in normal and tumor-bearing mice of tobacco mosaic virus. Biomacromolecules. 2013 Nov 11;14(11):4032-7.

9. Luo H#, Shi J#, Jin H#, Fan D, Lu L, Wang F*, Zhang Z*. An (125)I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo. Biomaterials. 2012 Jun;33(19):4843-50.

10. Shi J, Zhou Y, Chakraborty S, Kim YS, Jia B, Wang F, Liu S. Evaluation of 111In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics. 2011;1:322-40.

11. Shi J#, Liu TW#, Chen J, Green D, Jaffray D, Wilson BC, Wang F, Zheng G. Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. Theranostics. 2011;1:363-70.

12. Liu Z#, Shi J#, Jia B, Yu Z, Liu Y, Zhao H, Li F, Tian J, Chen X, Liu S, Wang F. Two (90)Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy. Mol Pharm. 2011, 8(2):591-599.

13. Shi J, Wang L, Kim YS, Zhai S, Jia B, Wang F, Liu S. 99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging. 2009, 36(11):1874-1884.

14. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, Liu S. 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjug Chem. 2009, 20(8):1559-1568.

15. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S. Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem. 2009, 20(4):750-759.

16. Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, Liu S.Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine -aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008, 51(24):7980-7990.



From:Jiyun Shi, 2019-11-01 update 


Print Text Size: A A A   Close


Institute of Biophysics, CAS    Address: 15 Datun Road, Chaoyang District, Beijing, 100101, China
Tel:8610-64889872    Fax: 8610-64871293    E-mail: office@ibp.ac.cn